Objective:To develop an HPLC method for the determination of fenbendazole and praziquantel in compound fenbendazole tablets. Methods:An InertSustain? C18 column(250 mm × 4. 6 mm,5 μm)was used. The mobile phase was acetonitrile-phosphate buffer(pH = 3)(48 ∶52)and the flow rate was 1. 0 ml·min-1 . The detection wavelength was 214 nm,the column temperature was 30 ℃ and the sample size was 10 μl. Results:The linear range of fenbendazole and praziquantel was 4. 545- 63. 630 μg·ml -1(r = 0. 999 9)and 0. 225- 3. 150 μg·ml-1(r = 0. 999 9),respectively. The average recovery was 101. 09%(RSD = 0. 28% ,n = 9)and 99. 47%(RSD = 0. 78% ,n = 9),respectively. Conclusion:The method is simple,fast, accurate and applicable in the determination of fenbendazole and praziquantel in compound fenbendazole tablets.

OBJECTIVE: To establish an HPLC method for the determination of the content of main components in racanisodamine hydrochloride(RH) injection.METHODS: The determination was performed on Phenomenex Luna C18 column with methanol-0.02% triethylamine(50∶50) used as mobile phase at a flow rate of 1.0 mL?min-1.The detecting wavelength was set at 220 nm;the column temperature was set at room temperature and the sample size was 20 ?L.RESULTS: The linear range of RH was 0.053～0.371 ?g?mL-1(r=0.999 9) and the average recover was 101.20%(RSD=0.23%,n=6).CONCLUSIONS: The method is proved to be simple,rapid,accurate and applicable for the determination of the content of RH in RH injection.

UMH polysaccharide was isolated and purified with alcohol precipitation from hot water extract of Umbilicaria hypococcinea Liano. By Sephadex G-150 column chromatography, UMH was shown to be a single homogeneous substance, sugar content 90.4%. By gas chromatogra phy analysis, UMH was composed of glucose, mannose and glucuronic aeid, their molecule ratio was about 45:1:9. Its mean molecular weight was estimated to be 40?104. IR analysis Periodate oxidation and Smith degradation showed that the main chain of UMH is composed,of ?(1→6) and (1→4) linkage, and was an acidic hetrosaccharide.

Objective To observe the clinical efficacy of combining Yuan-Primary and Luo-Connecting points in treating insomnia due to imbalance between heart and kidney, for providing novel method and evidence for the treatment of insomnia with acupuncture-moxibustion.Method Totally 100 insomnia patients due to imbalance between heart and kidney were randomized into a treatment group and a control group, 50 in each. The treatment group was intervened by acupuncture at Yuan-Primary and Luo-Connecting points, while the control group was by conventional acupuncture. The Pittsburgh Sleep Quality Index (PSQI), self-rating anxiety scale (SAS), and self-rating depression scale (SDS) were observed before and after intervention for efficacy evaluation.Result The PSQI item scores were significantly changed after intervention in both groups (P<0.05). The SAS and SDS scores were significantly different from that before treatment in both groups (P<0.05). After treatment, the SAS and SDS scores of the treatment group were significantly different from that of the control group (P<0.05). The recovery rate and total effective rate were 26.0% and 92.0% in the treatment group versus 12.0% and 86.0% in the control group, and there was a significant difference in comparing the recovery rate (P<0.05).Conclusion Combining use of Yuan-Primary and Luo-Connecting points is an effective approach in treating insomnia due to imbalance between heart and kidney.

Objective To discuss the clinical significant of detecting cytoplasm phospholipase A2 alpha (cPLA2α)in patients with chronic obstructive pulmonary disease (COPD).Methods Selected treated 90 cases of patients with COPD.According to the COPD severity classification standard,they were divided into mild group of 30 cases,moderate group of 25 cases and severe group of 35 cases.In the same period of physical examination,90 cases of normal lung function healthy were control group.Used Enzyme linked immunosorbent test (ELISA)to detect cPLA2αlevel of these groups.At the same time,detected cPLA2αexpression of these groups by RT-PCR.Results cPLA2αlevel in serum of mild group was (0.039 2±0.005 1)pg/ml,gene expression was (0.68±0.01),in moderate group (0.049 8±0.007 4)pg/ml and (0.92±0.02),in severe group (0.055 4±0.008 1)and (1.35±0.02).and in Healthy controls group (0.010 2±0.006 6)pg/ml and (0.11±0.01).There were significant differences among four groups (t = 3.013 ~ 5.817,5.039 ~ 11.667,P < 0.05).Conclusion Detection of blood cPLA2αcan indicate COPD severity,and cPLA2α is the new molecular targets of diagnosis,treatment and classifica-tion COPD.

Esophageal squamous cell carcinoma (ESCC) accounts for more than 90% of the confirmed cases of esophageal cancer in Asia, and the degree of malignancy is high. There is a growing number of research on ESCC immunotherapy, particularly programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1). Among them, the most studied PD-1/PD-L1 inhibitors in ESCC are nivolumab, pembrolizumab, camrelizumab, toripalimab, tislelizumab, atozolizumab, SHR-1316 and durvalumab. Some of the clinical trials of these drugs are still in progress, and some have initially shown good results.

Neuroimaging technology is the major means in the study of cerebral blood flow. This article reviews all kinds of neuroimaging technologies in identification of perihematomal penumbra in intracerebral hemorrhage,as well as the research status of perihematomal cerebral blood flow in intracerebral hemorrhage.

AIM: To observe the clinical effect of phacoemulsification and posterior chamber intraocular lens ( IOL) implantation in the treatment of unilateral high myopia combined with age-related cataract.
METHODS: A retrospective clinical study was carried out in a single ophthalmology center. All patients diagnosed of unilateral high myopia with age- related cataract were performed phacoemulsification and posterior chamber IOL implantation. The axial length of operation eye was ≥27mm, and the axial length of unoperated fellow eye was≤25mm. Visual acuity and complications were followed up for 1, 7d, 1, 3mo postoperative.
RESULTS:Thirty-three patients with average age 68. 8±9. 26 (41-87) y were enrolled in this study, 7 cases were men, 26 cases were women. The mean axial length of operation eyes was 29. 44±1. 80(27. 1-32. 71) mm and the mean axial length of unoperated fellow eyes was 23. 39±0.92 ( 21. 72 - 24. 90 ) mm. The average axial length difference of binocular eyes was 6. 06±1. 97(2. 78-9. 92) mm. The best corrected visual acuity ( BCVA ) increased from 0. 02±0. 02(light perception~0. 12) preoperatively to 0. 20±0. 20 ( 0. 02 - 0. 8 ) at 3mo postoperatively. There was statistically significant difference (t= -5. 278, P<0. 05). Among the 10 patients whose axial length difference of binocular eyes was 2. 01 - 5. 00mm, 60% of their postoperative BCVA were >0. 3. Among the 13 patients with binocular axial length difference of 5. 01-7. 00mm, 46.2% of BCVA were >0. 3,46.2% achieved 0. 05-0. 25. Another 10 patients of binocular axial length difference between 7. 01-9. 99mm, 90% of BCVA were <0. 3, of which 40% were<0. 05. No complications occurred during operative and postoperative .
CONCLUSION: Phacoemulsification and posterior chamber IOL implantation can effectively improve the postoperative visual acuity and it is safe for unilateral high myopic patients combined with age-related cataract. The recovery of visual acuity is related with binocular axial length difference.

OBJECTIVE:To determine the serum concentration of Deoxyschisandrin by RP-HPLC.METHODS:The chr-omatographic separation was performed on Phenomenex C18(250mm?4.6mm,5?m) column with column temperature at 30℃.The mobile phase consisted of methanol - water (80∶20) at a flow rate of 1mL?min-1. The detection wavelength was set at 252nm. RESULTS:The calibration curve of Deoxyschisandrin was linear in the concentration range from 0.52 to 33.28?g?mL-1 (r=0.999 6). The average recovery of deoxyschisandrin was (97.27?4.11)%(RSD=4.23%,n=9).CONCLUSION:The method is simple, accurate and sensitive, and it can be used for the determination of serum concentration of Deoxyschisandrin.